Phio Pharma Takes RXi’s Self-Delivering RNAi Technology, Refocuses On Immuno-Oncology
RXi thought it had solved the RNAi delivery issue but was focused on dermatology and ophthalmology. New CEO Dispersyn thought the platform offered more lucrative promise as a way of optimizing IO therapy.
You may also be interested in...
Biotech's asymmetrical, shorter RNAi therapeutics are water-soluble and therefore can be self-delivering. Lead candidate RXI-109 is being studied in both hypertrophic and retinal scarring, but the firm has new funding that could help it move into oncology.
Alkermes tells J.P. Morgan audience it hopes new combo Lybalvi and established Aristada will boost each other and the neuropsychiatric franchise. But the firm noted its addiction drug Vivitrol requires complicated commercial plan.
Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.